Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2016 (2016), Article ID 1083738, 12 pages
http://dx.doi.org/10.1155/2016/1083738
Review Article

Aptamers: A Feasible Technology in Cancer Immunotherapy

Aptamers Unit, Center for the Applied Medical Research (CIMA), Foundation for the Applied Medical Research (FIMA), Avenida Pío XII No. 55, 31008 Pamplona, Spain

Received 31 March 2016; Accepted 22 May 2016

Academic Editor: Ghislain Opdenakker

Copyright © 2016 M. M. Soldevilla et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Hanahan and R. A. Weinberg, “The hallmarks of cancer,” Cell, vol. 100, no. 1, pp. 57–70, 2000. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics,” CA: Cancer Journal for Clinicians, vol. 66, no. 1, pp. 7–30, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer facts & figures 2015,” in American Cancer Society. Cancer Facts & Figures, American Cancer Society, Atlanta, Ga, USA, 2015. View at Google Scholar
  5. C. Kyi and M. A. Postow, “Checkpoint blocking antibodies in cancer immunotherapy,” FEBS Letters, vol. 588, no. 2, pp. 368–376, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. “Ipilimumab,” Drugs in R&D, vol. 10, no. 2, pp. 97–110, 2010. View at Publisher · View at Google Scholar
  7. F. S. Hodi, S. J. O'Day, D. F. McDermott et al., “Improved survival with ipilimumab in patients with metastatic melanoma,” The New England Journal of Medicine, vol. 363, no. 8, pp. 711–723, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. E. J. Lipson and C. G. Drake, “Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma,” Clinical Cancer Research, vol. 17, no. 22, pp. 6958–6962, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Robert, L. Thomas, I. Bondarenko et al., “Ipilimumab plus dacarbazine for previously untreated metastatic melanoma,” The New England Journal of Medicine, vol. 364, no. 26, pp. 2517–2526, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. L. A. Raedler, “Keytruda (Pembrolizumab): first PD-1 inhibitor approved for previously treates unresectable or metastatic melanoma,” American Health & Drug Benefits, vol. 8, pp. 96–100, 2015. View at Google Scholar
  11. L. A. Raedler, “Opdivo (Nivolumab): second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma,” American Health & Drug Benefits, vol. 8, pp. 180–183, 2015. View at Google Scholar
  12. I. Melero, D. M. Berman, M. A. Aznar, A. J. Korman, J. L. P. Gracia, and J. Haanen, “Evolving synergistic combinations of targeted immunotherapies to combat cancer,” Nature Reviews Cancer, vol. 15, no. 8, pp. 457–472, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Attarwala, “TGN1412: from discovery to disaster,” Journal of Young Pharmacists, vol. 2, no. 3, pp. 332–336, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Bartkowiak and M. A. Curran, “4-1BB agonists: multi-potent potentiators of tumor immunity,” Frontiers in Oncology, vol. 5, article 117, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Naidoo, D. B. Page, B. T. Li et al., “Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies,” Annals of Oncology, vol. 26, no. 12, pp. 2375–2391, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. M. A. Postow, M. K. Callahan, and J. D. Wolchok, “Immune checkpoint blockade in cancer therapy,” Journal of Clinical Oncology, vol. 33, no. 17, pp. 1974–1982, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Shimazaki, E. J. Lepin, B. Wei et al., “Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines,” Clinical Cancer Research, vol. 14, no. 22, pp. 7367–7377, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Forsberg, N.-J. Skartved, M. Wallén-Öhman et al., “Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity,” Journal of Immunotherapy, vol. 33, no. 5, pp. 492–499, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. S. J. C. Van der Stegen, M. Hamieh, and M. Sadelain, “The pharmacology of second-generation chimeric antigen receptors,” Nature Reviews Drug Discovery, vol. 14, no. 7, pp. 499–509, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. A. M. Scott, J. D. Wolchok, and L. J. Old, “Antibody therapy of cancer,” Nature Reviews Cancer, vol. 12, no. 4, pp. 278–287, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. D. T. Rodgers, M. Mazagova, E. N. Hampton et al., “Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies,” Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 4, pp. E459–E468, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. A. D. Keefe, S. Pai, and A. Ellington, “Aptamers as therapeutics,” Nature Reviews Drug Discovery, vol. 9, no. 7, pp. 537–550, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Tuerk and L. Gold, “Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase,” Science, vol. 249, no. 4968, pp. 505–510, 1990. View at Publisher · View at Google Scholar · View at Scopus
  24. A. D. Ellington and J. W. Szostak, “In vitro selection of RNA molecules that bind specific ligands,” Nature, vol. 346, no. 6287, pp. 818–822, 1990. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Berezhnoy, C. A. Stewart, J. O. Mcnamara II et al., “Isolation and optimization of murine IL-10 receptor blocking oligonucleotide aptamers using high-throughput sequencing,” Molecular Therapy, vol. 20, no. 6, pp. 1242–1250, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Levay, R. Brenneman, J. Hoinka et al., “Identifying high-affinity aptamer ligands with defined cross-reactivity using high-throughput guided systematic evolution of ligands by exponential enrichment,” Nucleic Acids Research, vol. 43, no. 12, article e82, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. R. K. Mosing and M. T. Bowser, “Isolating aptamers using capillary electrophoresis-SELEX (CE-SELEX),” Methods in Molecular Biology, vol. 535, pp. 33–43, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. D. A. Daniels, H. Chen, B. J. Hicke, K. M. Swiderek, and L. Gold, “A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 26, pp. 15416–15421, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. R. White, C. Rusconi, E. Scardino et al., “Generation of species cross-reactive aptamers using ‘toggle’ SELEX,” Molecular Therapy, vol. 4, no. 6, pp. 567–573, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Oberthür, J. Achenbach, A. Gabdulkhakov et al., “Crystal structure of a mirror-image L-RNA aptamer (Spiegelmer) in complex with the natural L-protein target CCL2,” Nature Communications, vol. 6, article 6923, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Vater, F. Jarosch, K. Buchner, and S. Klussmann, “Short bioactive Spiegelmers to migraine-associated calcitonin gene-related peptide rapidly identified by a novel approach: tailored-SELEX,” Nucleic Acids Research, vol. 31, no. 21, article e130, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. T. A. Cooper, “In vivo SELEX in vertebrate cells,” Methods in Molecular Biology, vol. 118, pp. 405–417, 1999. View at Google Scholar · View at Scopus
  33. S. Kim, H. Shi, D.-K. Lee, and J. T. Lis, “Specific SR protein-dependent splicing substrates identified through genomic SELEX,” Nucleic Acids Research, vol. 31, no. 7, pp. 1955–1961, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. L. Cerchia and V. De Franciscis, “Nucleic acid-based aptamers as promising therapeutics in neoplastic diseases,” Methods in Molecular Biology, vol. 361, pp. 187–200, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Santulli-Marotto, S. K. Nair, C. Rusconi, B. Sullenger, and E. Gilboa, “Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity,” Cancer Research, vol. 63, no. 21, pp. 7483–7489, 2003. View at Google Scholar · View at Scopus
  36. S. Hervas-Stubbs, M. M. Soldevilla, H. Villanueva, U. Mancheño, M. Bendandi, and F. Pastor, “Identification of TIM3 2'-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy,” Oncotarget, vol. 7, no. 4, pp. 4522–4530, 2016. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Prodeus, A. Abdul-Wahid, N. W. Fischer, E. H. Huang, M. Cydzik, and J. Gariépy, “Targeting the PD-1/PD-L1 immune evasion axis with DNA aptamers as a novel therapeutic strategy for the treatment of disseminated cancers,” Molecular Therapy—Nucleic Acids, vol. 4, no. 4, article e237, 2015. View at Publisher · View at Google Scholar
  38. S. Gupta, M. Hirota, S. M. Waugh et al., “Chemically modified DNA aptamers bind interleukin-6 with high affinity and inhibit signaling by blocking its interaction with interleukin-6 receptor,” Journal of Biological Chemistry, vol. 289, no. 12, pp. 8706–8719, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. C. Meyer, K. Eydeler, E. Magbanua et al., “Interleukin-6 receptor specific RNA aptamers for cargo delivery into target cells,” RNA Biology, vol. 9, no. 1, pp. 67–80, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. F. Roth, A. C. De La Fuente, J. L. Vella, A. Zoso, L. Inverardi, and P. Serafini, “Aptamer-mediated blockade of IL4Rα triggers apoptosis of MDSCs and limits tumor progression,” Cancer Research, vol. 72, no. 6, pp. 1373–1383, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. E. W. Orava, N. Jarvik, Y. L. Shek, S. S. Sidhu, and J. Gariépy, “A short DNA aptamer that recognizes TNFα and blocks its activity in Vitro,” ACS Chemical Biology, vol. 8, no. 1, pp. 170–178, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. J. O. McNamara, D. Kolonias, F. Pastor et al., “Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice,” The Journal of Clinical Investigation, vol. 118, no. 1, pp. 376–386, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. C. M. Dollins, S. Nair, D. Boczkowski et al., “Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer,” Chemistry & Biology, vol. 15, no. 7, pp. 675–682, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. E. D. Pratico, B. A. Sullenger, and S. K. Nair, “Identification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40,” Nucleic Acid Therapeutics, vol. 23, no. 1, pp. 35–43, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. F. Pastor, M. M. Soldevilla, H. Villanueva et al., “CD28 aptamers as powerful immune response modulators,” Molecular Therapy—Nucleic Acids, vol. 2, article e98, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. M. M. Soldevilla, H. Villanueva, M. Bendandi, S. Inoges, A. López-Díaz de Cerio, and F. Pastor, “2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia,” Biomaterials, vol. 67, pp. 274–285, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. B. C. Wengerter, J. A. Katakowski, J. M. Rosenberg et al., “Aptamer-targeted antigen delivery,” Molecular Therapy, vol. 22, no. 7, pp. 1375–1387, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Boltz, B. Piater, L. Toleikis, R. Guenther, H. Kolmar, and B. Hock, “Bi-specific aptamers mediating tumor cell lysis,” Journal of Biological Chemistry, vol. 286, no. 24, pp. 21896–21905, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Zhou, K. Tiemann, P. Chomchan et al., “Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells,” Nucleic Acids Research, vol. 41, no. 7, pp. 4266–4283, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. E. Gilboa, J. McNamara II, and F. Pastor, “Use of oligonucleotide aptamer ligands to modulate the function of immune receptors,” Clinical Cancer Research, vol. 19, no. 5, pp. 1054–1062, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Oney, R. T. S. Lam, K. M. Bompiani et al., “Development of universal antidotes to control aptamer activity,” Nature Medicine, vol. 15, no. 10, pp. 1224–1228, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. K. M. Bompiani, R. S. Woodruff, R. C. Becker, S. M. Nimjee, and B. A. Sullenger, “Antidote control of aptamer therapeutics: the road to a safer class of drug agents,” Current Pharmaceutical Biotechnology, vol. 13, no. 10, pp. 1924–1934, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. K. S. Schmidt, S. Borkowski, J. Kurreck et al., “Application of locked nucleic acids to improve aptamer in vivo stability and targeting function,” Nucleic Acids Research, vol. 32, no. 19, pp. 5757–5765, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. J. C. Rohloff, A. D. Gelinas, T. C. Jarvis et al., “Nucleic acid ligands with protein-like side chains: modified aptamers and their use as diagnostic and therapeutic agents,” Molecular Therapy—Nucleic Acids, vol. 3, article e201, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. P. C. De Smidt, T. Le Doan, S. De Falco, and T. J. C. Van Berkel, “Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modifies the tissue distribution,” Nucleic Acids Research, vol. 19, no. 17, pp. 4695–4700, 1991. View at Publisher · View at Google Scholar · View at Scopus
  56. C. H. Lee, Y. J. Lee, J. H. Kim et al., “Inhibition of hepatitis c virus (HCV) replication by specific RNA aptamers against HCV NS5B RNA replicase,” Journal of Virology, vol. 87, no. 12, pp. 7064–7074, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. C. H. Lee, S.-H. Lee, J. H. Kim, Y.-H. Noh, G.-J. Noh, and S.-W. Lee, “Pharmacokinetics of a cholesterol-conjugated aptamer against the hepatitis C Virus (HCV) NS5B protein,” Molecular Therapy—Nucleic Acids, vol. 4, article e254, 2015. View at Publisher · View at Google Scholar · View at Scopus
  58. C. Da Pieve, E. Blackshaw, S. Missailidis, and A. C. Perkins, “PEGylation and biodistribution of an anti-MUC1 aptamer in MCF-7 tumor-bearing mice,” Bioconjugate Chemistry, vol. 23, no. 7, pp. 1377–1381, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. L. Tan, K. G. Neoh, E.-T. Kang, W. S. Choe, and X. Su, “PEGylated anti-MUC1 aptamer-doxorubicin complex for targeted drug delivery to MCF7 breast cancer cells,” Macromolecular Bioscience, vol. 11, no. 10, pp. 1331–1335, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. J. O. McNamara II, E. R. Andrechek, Y. Wang et al., “Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras,” Nature Biotechnology, vol. 24, no. 8, pp. 1005–1015, 2006. View at Publisher · View at Google Scholar · View at Scopus
  61. E. W. Orava, N. Cicmil, and J. Gariépy, “Delivering cargoes into cancer cells using DNA aptamers targeting internalized surface portals,” Biochimica et Biophysica Acta—Biomembranes, vol. 1798, no. 12, pp. 2190–2200, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. J. R. Kanwar, K. Roy, and R. K. Kanwar, “Chimeric aptamers in cancer cell-targeted drug delivery,” Critical Reviews in Biochemistry and Molecular Biology, vol. 46, no. 6, pp. 459–477, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. D. H. J. Bunka and P. G. Stockley, “Aptamers come of age—at last,” Nature Reviews Microbiology, vol. 4, no. 8, pp. 588–596, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. G. Zhou, G. Wilson, L. Hebbard et al., “Aptamers: a promising chemical antibody for cancer therapy,” Oncotarget, vol. 7, no. 12, pp. 13446–13463, 2016. View at Publisher · View at Google Scholar
  65. D. Ricklin and J. D. Lambris, “Complement-targeted therapeutics,” Nature Biotechnology, vol. 25, no. 11, pp. 1265–1275, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. P. Sundaram, H. Kurniawan, M. E. Byrne, and J. Wower, “Therapeutic RNA aptamers in clinical trials,” European Journal of Pharmaceutical Sciences, vol. 48, no. 1-2, pp. 259–271, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. J. C. Gilbert, T. DeFeo-Fraulini, R. M. Hutabarat et al., “First-in-human evaluation of anti-von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers,” Circulation, vol. 116, no. 23, pp. 2678–2686, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. B. Jilma, P. Paulinska, P. Jilma-Stohlawetz, J. C. Gilbert, R. Hutabarat, and P. Knöbl, “A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease,” Thrombosis and Haemostasis, vol. 104, no. 3, pp. 563–570, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. M. M. Gubin, X. Zhang, H. Schuster et al., “Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens,” Nature, vol. 515, no. 7528, pp. 577–581, 2014. View at Publisher · View at Google Scholar · View at Scopus
  70. N. A. Rizvi, M. D. Hellmann, A. Snyder et al., “Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer,” Science, vol. 348, no. 6230, pp. 124–128, 2015. View at Publisher · View at Google Scholar · View at Scopus
  71. T. N. Schumacher and R. D. Schreiber, “Neoantigens in cancer immunotherapy,” Science, vol. 348, no. 6230, pp. 69–74, 2015. View at Publisher · View at Google Scholar · View at Scopus
  72. F. Pastor, D. Kolonias, P. H. Giangrande, and E. Gilboa, “Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay,” Nature, vol. 465, no. 7295, pp. 227–230, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. E. Gilboa, A. Berezhnoy, and B. Schrand, “Reducing toxicity of immune therapy using aptamer-targeted drug delivery,” Cancer Immunology Research, vol. 3, no. 11, pp. 1195–1200, 2015. View at Publisher · View at Google Scholar
  74. A. Herrmann, S. J. Priceman, P. Swiderski et al., “CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells,” The Journal of Clinical Investigation, vol. 124, no. 7, pp. 2977–2987, 2014. View at Google Scholar
  75. M. Kortylewski, M. Kujawski, A. Herrmann et al., “Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy,” Cancer Research, vol. 69, no. 6, pp. 2497–2505, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Kortylewski, P. Swiderski, A. Herrmann et al., “In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses,” Nature Biotechnology, vol. 27, no. 10, pp. 925–932, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. A. Gros, P. F. Robbins, X. Yao et al., “PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors,” The Journal of Clinical Investigation, vol. 124, no. 5, pp. 2246–2259, 2014. View at Publisher · View at Google Scholar · View at Scopus
  78. K. Hoehlig, C. Maasch, N. Shushakova et al., “A novel C5a-neutralizing mirror-image (L-)aptamer prevents organ failure and improves survival in experimental sepsis,” Molecular Therapy, vol. 21, no. 12, pp. 2236–2246, 2013. View at Publisher · View at Google Scholar · View at Scopus
  79. B. Schrand, A. Berezhnoy, R. Brenneman, A. Williams, A. Levay, and E. Gilboa, “Reducing toxicity of 4–1BB costimulation: targeting 4–1BB ligands to the tumor stroma with bi-specific aptamer conjugates,” OncoImmunology, vol. 4, no. 3, pp. 1–3, 2015. View at Publisher · View at Google Scholar · View at Scopus
  80. M. M. Soldevilla, H. Villanueva, N. Casares et al., “MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells,” Oncotarget, 2016. View at Publisher · View at Google Scholar
  81. L. Niu, S. Strahotin, B. Hewes et al., “Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice,” Journal of Immunology, vol. 178, no. 7, pp. 4194–4213, 2007. View at Publisher · View at Google Scholar · View at Scopus
  82. F. Pastor, D. Kolonias, J. O. McNamara II, and E. Gilboa, “Targeting 4-1BB costimulation to disseminated tumor lesions with Bi-specific oligonucleotide aptamers,” Molecular Therapy, vol. 19, no. 10, pp. 1878–1886, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. J. P. Their, “Epithelial-mesenchymal transitions in tumour progression,” Nature Reviews Cancer, vol. 2, no. 6, pp. 442–454, 2002. View at Publisher · View at Google Scholar · View at Scopus
  84. M. Dean, T. Fojo, and S. Bates, “Tumour stem cells and drug resistance,” Nature Reviews Cancer, vol. 5, no. 4, pp. 275–284, 2005. View at Publisher · View at Google Scholar · View at Scopus
  85. J. A. Holbrook, G. Neu-Yilik, M. W. Hentze, and A. E. Kulozik, “Nonsense-mediated decay approaches the clinic,” Nature Genetics, vol. 36, no. 8, pp. 801–808, 2004. View at Publisher · View at Google Scholar · View at Scopus
  86. J. El-Bchiri, A. Guilloux, P. Dartigues et al., “Nonsense-mediated mRNA decay impacts MSI-driven carcinogenesis and anti-tumor immunity in colorectal cancers,” PLoS ONE, vol. 3, no. 7, Article ID e2583, 2008. View at Publisher · View at Google Scholar · View at Scopus
  87. A. Berezhnoy, I. Castro, A. Levay, T. R. Malek, and E. Gilboa, “Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity,” Journal of Clinical Investigation, vol. 124, no. 1, pp. 188–197, 2014. View at Publisher · View at Google Scholar · View at Scopus
  88. T. Lozano, M. M. Soldevilla, N. Casares et al., “Targeting inhibition of Foxp3 by a CD28 2′-Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy,” Biomaterials, vol. 91, pp. 73–80, 2016. View at Publisher · View at Google Scholar
  89. N. Casares, F. Rudilla, L. Arribillaga et al., “A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice,” Journal of Immunology, vol. 185, no. 9, pp. 5150–5159, 2010. View at Publisher · View at Google Scholar · View at Scopus